Evaluating the Effectiveness of Semaglutide in Managing Knee Osteoarthritis
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on December 13th, 2024
|
Obesity greatly increases the risk of knee osteoarthritis due to the added pressure on the joint and the metabolic dysfunction that triggers inflammation. Previous research has shown that weight management interventions, such as calorie-restricted diets and bariatric surgery, can help reduce the severity of osteoarthritis. Semaglutide, a GLP-1 receptor agonist commonly used to treat diabetes, has demonstrated significant weight loss effects. As a result, a study funded by Novo Nordisk was conducted to evaluate the potential of using semaglutide to manage osteoarthritis.
The clinical study involved 407 participants with an average age of 56 years and a mean body mass index (BMI) of 40.3. These individuals were diagnosed with knee osteoarthritis according to the criteria established by the American College of Rheumatology. Baseline assessment using the Western Ontario and McMaster Osteoarthritis Index (WOMAC) yielded an average score of 70.9, with 100 indicating the most severe disease. Participants were randomly assigned to receive subcutaneous injections of either a placebo or semaglutide, starting at a dose of 0.24 mg, which was gradually increased to 2.4 mg over 16 weeks. After 68 weeks of treatment, the researchers found that semaglutide significantly reduced the severity of osteoarthritis, with an average reduction of 41.7 points on the WOMAC score, compared to a 27.5-point reduction in the placebo group. This improvement in osteoarthritis symptoms was accompanied by a significant reduction in body weight, with a 13.7% decrease from baseline in the semaglutide group, compared to a 3.2% reduction in the placebo group. The authors noted that 6.7% of participants treated with semaglutide discontinued treatment, with gastrointestinal issues being the most commonly reported adverse event. The trial also observed that patients using semaglutide had a reduced need for analgesics such as NSAIDs or acetaminophen. However, to fully assess the effects of semaglutide on osteoarthritis and associated inflammation, the study could have also monitored changes in inflammation indicative biomarkers such as C-reactive protein.
The clinical study involved 407 participants with an average age of 56 years and a mean body mass index (BMI) of 40.3. These individuals were diagnosed with knee osteoarthritis according to the criteria established by the American College of Rheumatology. Baseline assessment using the Western Ontario and McMaster Osteoarthritis Index (WOMAC) yielded an average score of 70.9, with 100 indicating the most severe disease. Participants were randomly assigned to receive subcutaneous injections of either a placebo or semaglutide, starting at a dose of 0.24 mg, which was gradually increased to 2.4 mg over 16 weeks. After 68 weeks of treatment, the researchers found that semaglutide significantly reduced the severity of osteoarthritis, with an average reduction of 41.7 points on the WOMAC score, compared to a 27.5-point reduction in the placebo group. This improvement in osteoarthritis symptoms was accompanied by a significant reduction in body weight, with a 13.7% decrease from baseline in the semaglutide group, compared to a 3.2% reduction in the placebo group. The authors noted that 6.7% of participants treated with semaglutide discontinued treatment, with gastrointestinal issues being the most commonly reported adverse event. The trial also observed that patients using semaglutide had a reduced need for analgesics such as NSAIDs or acetaminophen. However, to fully assess the effects of semaglutide on osteoarthritis and associated inflammation, the study could have also monitored changes in inflammation indicative biomarkers such as C-reactive protein.